

Application No.: 10/804,845

REMARKS

The following claims are pending in the application: 1 – 34

The following claims have been amended: 13 – 16

The following claims have been deleted or 17 – 34

withdrawn:

The following claims have been added: N/A

As a result of the foregoing Amendment, the following claims remain pending in the application: 1 – 16.

This supplemental response is being filed in order to re-number the claims in consecutive numeric order and to correct the dependency notations to reflect the correct claim number. No other amendments to the claims have been made.

Election/Restriction Requirement

The Examiner previously required restriction of the claims between five groups of claims:

Group I including claims 1 – 16 drawn to a method of treating diabetes in a human;

Group II including claim 17 drawn to a pharmaceutical composition for suppressing or reducing the immune response;

Group III including claims 18 - 30 drawn to a method to increase insulin production in a diabetes patient with beta cell antibodies;

Group IV including claims 31 – 32 drawn to a method to treat beta cell inflammation; and

Group V including claims 33 – 34 drawn to a pharmaceutical composition for the treatment of diabetes.

Application No. 10/804,845

In response, Applicants elected to prosecute the claims drawn to a method of treating diabetes in humans, which are covered by claims 1 – 16. Applicants' election is without traverse.

Applicants respectfully request that the Examiner enter the following Amendment and consider the following Remarks. Applicants respectfully request that the Examiner reconsider and again examine the present application and claims in light thereof.

CONCLUSION

In view of the foregoing amendment and accompanying remarks, the Applicants respectfully submit that the present application is properly in condition for allowance and may be passed to issuance upon payment of the appropriate fees.

Telephone inquiry to the undersigned in order to clarify or otherwise expedite prosecution of the subject application is respectfully encouraged.

Respectfully submitted,

Date: June 28, 2006

By:


Roger A. Gilcrest, Registration No.: 31,954

Schottenstein, Zox & Dunn Co., L.P.A.
250 West Street
Columbus, Ohio 43215
Mailing Address:
P.O. Box 165020
Columbus, Ohio 43216-5020
P: (614) 462-1055
F: (614) 222-3437
Email: rgilcrest@szd.com